The summation on this subsection: Having examined the presented data and looking ahead, one can expect that further exploration of mortalin–p53 interactions supported by studies with in silico modeling and biosimulation will eventually yield suitable HSPA9-targeting agents which will be useful for treating patients with breast cancer. Here, HSPA9 is linked to breast carcinoma.